Phathom Pharmaceuticals/$PHAT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
- Ticker
- $PHAT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 371
- Headquarters
- Florham Park, United States
- Website
- www.phathompharma.com
PHAT Metrics
BasicAdvanced
$558M
-
-$1.27
0.50
-
Price and volume
Market cap
$558M
Beta
0.5
52-week high
$18.31
52-week low
$6.52
Average daily volume
1.3M
Financial strength
Current ratio
1.924
Quick ratio
1.82
Long term debt to equity
-1.493
Total debt to equity
-1.603
Interest coverage (TTM)
-0.64%
Profitability
EBITDA (TTM)
-40.134
Gross margin (TTM)
82.92%
Net profit margin (TTM)
-41.34%
Operating margin (TTM)
-16.96%
Revenue per employee (TTM)
$650,000
Management effectiveness
Return on assets (TTM)
-8.80%
Return on equity (TTM)
26.42%
Valuation
Price to revenue (TTM)
2.296
Price to book
-1.64
Price to tangible book (TTM)
-1.64
Price to free cash flow (TTM)
-14.905
Free cash flow yield (TTM)
-6.71%
Free cash flow per share (TTM)
-0.472
Growth
Revenue change (TTM)
110.16%
Earnings per share change (TTM)
-73.14%
3-year earnings per share growth (CAGR)
-33.60%
What the Analysts think about PHAT
Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.
Analyst projections of the future price of Phathom Pharmaceuticals stock.
Bulls say / Bears say
Q2 revenue rose 88% year on year to $74.3 million, while operating costs fell 33%. Phathom also reached operating profitability excluding stock-based compensation, suggesting the business is beginning to gain operating leverage. (SEC)
VOQUEZNA prescriptions grew to about 325,000 in Q2, with covered prescriptions up 79% year on year and making up 64% of the quarter’s total. Continued growth in insured use would support the commercial case beyond cash-pay demand. (GlobeNewswire)
Phathom has potential label-expansion opportunities in eosinophilic oesophagitis and as-needed treatment for non-erosive GERD. The EoE Phase 2 study is fully enrolled, with results expected in Q4, and a Phase 3 as-needed trial is planned; positive results could broaden VOQUEZNA’s use. (GlobeNewswire)
Phathom cut its 2026 revenue outlook to $310–325 million from $320–345 million, citing friction physicians face in obtaining VOQUEZNA for patients. That points to access hurdles which may limit uptake, particularly among less severe GERD patients. (SEC)
At June 30, Phathom had $182.5 million in cash against a $175 million term loan and a $384.9 million revenue-interest financing liability; first-half interest expense was $30.9 million. Those obligations could absorb cash generated by the launch and leave less room for investment. (StockTitan)
Competition from another potassium-competitive acid blocker could put pressure on VOQUEZNA’s pricing or reimbursement terms. Q2 earnings-call coverage reported that management saw possible effects on gross-to-net discounts, even though it did not expect a major impact on growth in 2027. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
PHAT Financial Performance
Revenues and expenses
PHAT Earnings Performance
Company profitability
Upcoming events
No upcoming events
PHAT News
AllArticlesVideos
Funds containing PHAT
Fund name | Fund size | $PHAT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.